[Radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17) : A multicentre phase III trial].
作者信息
Süß Christoph, Kölbl Oliver
机构信息
Klinik und Poliklinik für Strahlentherapie, Universitätsklinikum Regensburg, Franz-Josef-Strauß-Allee 11, 93053, Regensburg, Deutschland.
出版信息
Strahlenther Onkol. 2021 Oct;197(10):946-949. doi: 10.1007/s00066-021-01826-w. Epub 2021 Aug 11.
Abstract
摘要
相似文献
1
[Radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17) : A multicentre phase III trial].早期不良型霍奇金淋巴瘤的放疗（GHSG HD17）：一项多中心III期试验
Strahlenther Onkol. 2021 Oct;197(10):946-949. doi: 10.1007/s00066-021-01826-w. Epub 2021 Aug 11.
2
PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial.PET 引导的早期不利型霍奇金淋巴瘤放疗省略（GHSG HD17）：一项多中心、开放标签、随机、3 期临床试验。
Lancet Oncol. 2021 Feb;22(2):223-234. doi: 10.1016/S1470-2045(20)30601-X.
3
Involved-node radiotherapy in early-stage Hodgkin's lymphoma. Definition and guidelines of the German Hodgkin Study Group (GHSG).早期霍奇金淋巴瘤的受累淋巴结放疗。德国霍奇金淋巴瘤研究组（GHSG）的定义与指南
Strahlenther Onkol. 2008 Aug;184(8):406-10. doi: 10.1007/s00066-008-1882-7.
4
The development of quality assurance programs for radiotherapy within the German Hodgkin Study Group (GHSG). Introduction, continuing work, and results of the radiotherapy reference panel.德国霍奇金淋巴瘤研究组（GHSG）内放射治疗质量保证计划的发展。放疗参考小组的介绍、持续工作及成果。
Strahlenther Onkol. 2005 Sep;181(9):557-66. doi: 10.1007/s00066-005-1437-0.
5
Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14).早期预后不良霍奇金淋巴瘤患者的强化治疗：德国霍奇金研究组（GHSG HD14）随机、国际 3 期试验的长期随访结果
Lancet Haematol. 2021 Apr;8(4):e278-e288. doi: 10.1016/S2352-3026(21)00029-6.
6
A Contribution to solve the problem of the need for consolidative radiotherapy after intensive chemotherapy in advanced stages of Hodgkin's lymphoma--analysis of a quality control program initiated by the radiotherapy reference center of the German Hodgkin Study Group (GHSG).对解决晚期霍奇金淋巴瘤强化化疗后巩固性放疗必要性问题的一项贡献——德国霍奇金淋巴瘤研究组（GHSG）放疗参考中心启动的质量控制项目分析
Int J Radiat Oncol Biol Phys. 2007 Nov 15;69(4):1187-92. doi: 10.1016/j.ijrobp.2007.04.035. Epub 2007 Aug 20.
7
8
The German Hodgkin Study Group risk model is useful for Hodgkin lymphoma patients receiving radiotherapy after autologous stem cell transplant.德国霍奇金淋巴瘤研究组风险模型对接受自体干细胞移植后放疗的霍奇金淋巴瘤患者有用。
Cancer Radiother. 2019 Sep;23(5):378-384. doi: 10.1016/j.canrad.2019.02.002. Epub 2019 Jun 6.
9
Radiotherapy for children and adolescents with early-stage classical Hodgkin lymphoma.儿童和青少年早期经典型霍奇金淋巴瘤的放射治疗
Lancet Oncol. 2023 Jun;24(6):e230. doi: 10.1016/S1470-2045(23)00211-5.
10
Evolution of radiation therapy within the German Hodgkin Study Group trials.德国 Hodgkin 研究组试验中放射治疗的演变。
J Natl Compr Canc Netw. 2011 Sep 1;9(9):1073-80. doi: 10.6004/jnccn.2011.0088.
本文引用的文献
1
Fondazione Italiana Linfomi (FIL) expert consensus on the use of intensity-modulated and image-guided radiotherapy for Hodgkin's lymphoma involving the mediastinum.意大利淋巴瘤基金会（FIL）关于纵隔受累霍奇金淋巴瘤调强放疗和图像引导放疗应用的专家共识。
Radiat Oncol. 2020 Mar 12;15(1):62. doi: 10.1186/s13014-020-01504-8.
2
Inclusion of heart substructures in the optimization process of volumetric modulated arc therapy techniques may reduce the risk of heart disease in Hodgkin's lymphoma patients.在容积调强弧形治疗技术的优化过程中纳入心脏亚结构可能会降低霍奇金淋巴瘤患者心脏病的风险。
Radiother Oncol. 2019 Sep;138:52-58. doi: 10.1016/j.radonc.2019.05.009. Epub 2019 May 27.
3
Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.霍奇金淋巴瘤：ESMO 诊断、治疗及随访临床实践指南
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv19-iv29. doi: 10.1093/annonc/mdy080.
4
PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group.PET 引导治疗晚期霍奇金淋巴瘤（HD18）：德国霍奇金研究组开展的一项开放标签、国际、随机 3 期临床试验的最终结果。
Lancet. 2017 Dec 23;390(10114):2790-2802. doi: 10.1016/S0140-6736(17)32134-7. Epub 2017 Oct 20.
5
Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial.早期正电子发射断层扫描反应适应性治疗 I 期和 II 期霍奇金淋巴瘤：随机 EORTC/LYSA/FIL H10 试验的最终结果。
J Clin Oncol. 2017 Jun 1;35(16):1786-1794. doi: 10.1200/JCO.2016.68.6394. Epub 2017 Mar 14.
6
Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma.早期霍奇金淋巴瘤的 PET 导向治疗试验结果。
N Engl J Med. 2015 Apr 23;372(17):1598-607. doi: 10.1056/NEJMoa1408648.
7
Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial.早期预后不良型霍奇金淋巴瘤的剂量强化治疗：德国霍奇金研究组 HD14 试验的最终分析。
J Clin Oncol. 2012 Mar 20;30(9):907-13. doi: 10.1200/JCO.2011.38.5807. Epub 2012 Jan 23.
8
Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial.早期不利霍奇金淋巴瘤（HL）治疗后女性幸存者的生育能力和性腺功能。德国霍奇金研究组 HD14 试验。
Ann Oncol. 2012 Jul;23(7):1818-25. doi: 10.1093/annonc/mdr575. Epub 2012 Jan 6.
9
Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials.在德国霍奇金淋巴瘤研究组（GHSG）临床试验中接受治疗的霍奇金淋巴瘤患者的男性生育力评估。
Ann Oncol. 2008 Oct;19(10):1795-801. doi: 10.1093/annonc/mdn376. Epub 2008 Jun 9.
10
Gonadal function following ABVD therapy for Hodgkin's disease.霍奇金病患者接受ABVD治疗后的性腺功能
Am J Clin Oncol. 1997 Aug;20(4):354-7. doi: 10.1097/00000421-199708000-00006.
Zotero 插件